Cardiac β-adrenergic receptor activation mediates distinct and cell type-dependent changes in the expression and distribution of connexin 43
- PMID: 32578931
- PMCID: PMC7412418
- DOI: 10.1111/jcmm.15469
Cardiac β-adrenergic receptor activation mediates distinct and cell type-dependent changes in the expression and distribution of connexin 43
Abstract
Activation of the sympatho-β-adrenergic receptors (β-ARs) system is a hallmark of heart failure, leading to fibrosis and arrhythmias. Connexin 43 (Cx43) is the most abundant gap junctional protein in the myocardium. Current knowledge is limited regarding Cx43 remodelling in diverse cell types in the diseased myocardium and the underlying mechanism. We studied cell type-dependent changes in Cx43 remodelling due to β-AR overactivation and molecular mechanisms involved. Mouse models of isoproterenol stimulation or transgenic cardiomyocyte overexpression of β2 -AR were used, which exhibited cardiac fibrosis and up-regulated total Cx43 abundance. In both models, whereas Cx43 expression in cardiomyocytes was reduced and more laterally distributed, fibroblasts exhibited elevated Cx43 expression and enhanced gap junction communication. Mechanistically, activation of β2 -AR in fibroblasts in vitro elevated Cx43 expression, which was abolished by the β2 -antagonist ICI-118551 or protein kinase A inhibitor H-89, but simulated by the adenylyl cyclase activator forskolin. Our in vitro and in vivo data showed that β-AR activation-induced production of IL-18 sequentially stimulated Cx43 expression in fibroblasts in a paracrine fashion. In summary, our findings demonstrate a pivotal role of β-AR in mediating distinct and cell type-dependent changes in the expression and distribution of Cx43, leading to pathological gap junction remodelling in the myocardium.
Keywords: IL-18; cardiac fibrosis; connexin 43; gap junction remodelling; β-AR activation.
© 2020 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd.
Conflict of interest statement
None declared.
Figures
Similar articles
-
Regulation of gap-junction protein connexin 43 by beta-adrenergic receptor stimulation in rat cardiomyocytes.Acta Pharmacol Sin. 2009 Jul;30(7):928-34. doi: 10.1038/aps.2009.92. Acta Pharmacol Sin. 2009. PMID: 19574999 Free PMC article.
-
Subchronic alpha- and beta-adrenergic regulation of cardiac gap junction protein expression.FASEB J. 2006 Feb;20(2):365-7. doi: 10.1096/fj.05-4871fje. Epub 2005 Dec 13. FASEB J. 2006. PMID: 16352648
-
Adrenergic control of cardiac gap junction function and expression.Naunyn Schmiedebergs Arch Pharmacol. 2011 Apr;383(4):331-46. doi: 10.1007/s00210-011-0603-4. Epub 2011 Feb 12. Naunyn Schmiedebergs Arch Pharmacol. 2011. PMID: 21318337 Review.
-
Opposing and synergistic effects of cyclic mechanical stretch and α- or β-adrenergic stimulation on the cardiac gap junction protein Cx43.Pharmacol Res. 2010 Dec;62(6):506-13. doi: 10.1016/j.phrs.2010.08.002. Epub 2010 Aug 10. Pharmacol Res. 2010. PMID: 20705136
-
[Remodeling of cardiac gap junctions and arrhythmias].Sheng Li Xue Bao. 2011 Dec 25;63(6):586-92. Sheng Li Xue Bao. 2011. PMID: 22193455 Review. Chinese.
Cited by
-
Remodeling of Cardiac Gap Junctional Cell-Cell Coupling.Cells. 2021 Sep 14;10(9):2422. doi: 10.3390/cells10092422. Cells. 2021. PMID: 34572071 Free PMC article. Review.
-
β2-Adrenergic receptor agonist enhances the bystander effect of HSV-TK/GCV gene therapy in glioblastoma multiforme via upregulation of connexin 43 expression.Mol Ther Oncolytics. 2022 Jun 6;26:76-87. doi: 10.1016/j.omto.2022.05.010. eCollection 2022 Sep 15. Mol Ther Oncolytics. 2022. PMID: 35795095 Free PMC article.
-
New Insights on the Role of Connexins and Gap Junctions Channels in Adipose Tissue and Obesity.Int J Mol Sci. 2021 Nov 10;22(22):12145. doi: 10.3390/ijms222212145. Int J Mol Sci. 2021. PMID: 34830025 Free PMC article. Review.
-
Orexin/hypocretin system dysfunction in patients with Takotsubo syndrome: A novel pathophysiological explanation.Front Cardiovasc Med. 2022 Nov 3;9:1016369. doi: 10.3389/fcvm.2022.1016369. eCollection 2022. Front Cardiovasc Med. 2022. PMID: 36407467 Free PMC article.
-
Activation of Hippo signaling pathway mediates mitochondria dysfunction and dilated cardiomyopathy in mice.Theranostics. 2021 Aug 21;11(18):8993-9008. doi: 10.7150/thno.62302. eCollection 2021. Theranostics. 2021. PMID: 34522223 Free PMC article.
References
-
- Cohn JN, Levine TB, Olivari MT, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med. 1984;311:819‐823. - PubMed
-
- Manolis AJ, Poulimenos LE, Kallistratos MS, Gavras I, Gavras H. Sympathetic overactivity in hypertension and cardiovascular disease. Curr Vasc Pharmacol. 2014;12:4‐15. - PubMed
-
- Nguyen MN, Kiriazis H, Ruggiero D, et al. Spontaneous ventricular tachyarrhythmias in beta2‐adrenoceptor transgenic mice in relation to cardiac interstitial fibrosis. Am J Physiol Heart Circ Physiol. 2015;309:H946‐H957. - PubMed
-
- Du XJ, Cox HS, Dart AM, Esler MD. Sympathetic activation triggers ventricular arrhythmias in rat heart with chronic infarction and failure. Cardiovasc Res. 1999;43:919‐929. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous